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Pharmacology, University College London, Gower Street,
London WC1E 6BT, UKAbstract—Osteoarthritis (OA) remains one of the greatest
healthcare burdens in western society, with chronic debili-
tating pain-dominating clinical presentation yet therapeutic
strategies are inadequate in many patients. Development
of better analgesics is contingent on improved understand-
ing of the molecular mechanisms mediating OA pain.
Voltage-gated calcium channels 2.2 (Cav2.2) play a critical
role in spinal nociceptive transmission, therefore blocking
Cav2.2 activity represents an attractive opportunity for OA
pain treatment, but the only available licensed Cav2.2 antag-
onist ziconitide (PrilatTM) is of limited use. TROX-1 is an
orally available, use dependent and state-selective Cav2
antagonist, exerting its analgesic eﬀect primarily via
Cav2.2 blockade, with an improved therapeutic window com-
pared with ziconitide. Using a rat model of monosodium
iodoacetate (MIA), 2 mg, induced OA we used in vivo elec-
trophysiology to assess the eﬀects of spinal or systemic
administration of TROX-1 on the evoked activity of wide
dynamic range spinal dorsal horn neurons in response to
electrical, natural mechanical (dynamic brush and von
Frey 2, 8, 26 and 6 g) and thermal (40, 45 and 45 C) stimuli
applied to the peripheral receptive ﬁeld. MIA injection into
the knee joint resulted in mechanical hypersensitivity of the
ipsilateral hind paw and weight-bearing asymmetry. Spinal
administration of TROX-1 (0.1 and 1 lg/50 ll) produced a
signiﬁcant dose-related inhibition of dynamic brush,
mechanical (von Frey ﬁlament (vF) 8, 26 and 60 g) and nox-
ious thermal-(45 and 48 C) evoked neuronal responses in
MIA rats only. Systemic administration of TROX-1 produced
a signiﬁcant inhibition of the mechanical-(vF 8, 26 and 60 g)
evoked neuronal responses in MIA rats. TROX-1 did not pro-
duce any signiﬁcant eﬀect on any neuronal measure in
Sham controls. Our in vivo electrophysiological results
demonstrate a pathological state-dependent eﬀect of
TROX-1, which suggests an increased functional role of
Cav2, likely Cav2.2, channels in mediating OA pain.http://dx.doi.org/10.1016/j.neuroscience.2015.07.073
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INTRODUCTION
Osteoarthritis (OA) is the most common form of joint
disease, has a steadily rising prevalence due to an
increasingly elderly and obese society, and represents
one of the biggest contributors to the socioeconomic
healthcare burden in the western world (Reginster,
2002). It is characterized by loss of articular cartilage,
subchondral bone remodeling and inﬂammation and swel-
ling of the joint. Perhaps the most deﬁning feature of clin-
ical OA is chronic debilitating joint pain. This can range
from mild (dull aches) to severe (sharp stabbing pain) in
the same patient, with consequent co-morbidities (mood
and sleep problems) and decreased quality of life
(Murphy et al., 2011). This would suggest abnormalities
of peripheral and central processing of pain. Without
any pharmacological disease-modifying therapies cur-
rently in use, treatment is predominantly analgesic: parac-
etamol forms the current ﬁrst line, followed by NSAIDs,
opioids and steroids in line with disease progression
and the severity of pain. However these medicines are
inadequate for many OA patients due to limited analgesic
eﬃcacy and safety issues, especially with prolonged use.
This signiﬁcant unmet clinical burden necessitates a
greater understanding of the mechanisms that initiate
and maintain OA pain in order to develop alternative,
more eﬀective analgesics.
Voltage-gated calcium channels (VGCCs) on
nociceptors play an important role in nociceptive
signaling; they are critical for neurotransmitter release,
the regulation of neuronal excitability and intracellular
changes (Lee, 2013). Studies have implicated an increase
in voltage-gated Ca2+ currents, and their potential redistri-
bution to central or peripheral terminals, contributing to
inﬂammation-induced increases in aﬀerent input (Neubert
et al., 2000; Bilici et al., 2001; Lu et al., 2010; Takasusuki
and Yaksh, 2011). In addition, an increased expression of
the alpha2delta auxiliary subunit of VGCCs was observed
within the ipsilateral dorsal horn of MIA-(monosodium/licenses/by/4.0/).
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and the alpha2delta ligand, gabapentin, reduced modali-
ties of hyperalgesia in two diﬀerent models of knee arthritis
(Lu and Westlund, 1999; Vonsy et al., 2008). Further, a
subset of OA patients also exhibit nerve injury-like pain
and the licensed drugs gabapentin and pregabalin, that
modulate VGCC activity, have proven analgesic eﬃcacy
for neuropathic pain treatment (Hochman et al., 2011;
Ohtori et al., 2012; Roubille et al., 2014). Taken together,
these studies suggest that inhibiting VGCCs, in order to
reduce the synaptic transmission of the pain signal, is a
promising avenue for the treatment of OA pain.
The N-type (Cav2.2) is of particular interest for chronic
pain treatment. These channels are located both pre- and
post-synaptically on spinal central aﬀerent terminals and
second-order neurons, and are crucial for
neurotransmitter release, such as calcitonin gene-
related peptide (CGRP), substance P (SP), and
glutamate and, hence, pain transduction within the CNS
(Lee, 2013). The potential of targeting this point of noci-
ceptive convergence was demonstrated by studies show-
ing that selective conotoxins prevented the onset of
hyperalgesia or allodynia, and transgenic mice lacking
the Cav2.2 gene displayed an altered pain behavioral phe-
notype (Kim et al., 2001; Saegusa et al., 2001; Scott et al.,
2002). Consequently, the selective Cav2.2 blocker, ziconi-
tide (Prialt), was successfully licensed for the treatment
of intractable chronic pain. However ziconitide is of limited
use due to a narrow therapeutic window and must be
given intrathecally to prevent systemic side eﬀects.
Newer therapies, derived and reﬁned from the great pro-
mise of N-type blockers such as Ziconotide, with greater
therapeutic ratios and more favorable routes of adminis-
tration could dramatically improve chronic pain treatment.
To this end, an orally available, state-dependent Cav2
channel blocker, N-triazole oxindole (TROX-1) was
recently developed (Abbadie et al., 2010; Swensen
et al., 2012). TROX-1 inhibits all three members of the
Cav2 subfamily with equal potency, but, its analgesic
activity was quashed in Cav2.2-deﬁcient mice and side
eﬀects normally caused by block of Cav2.1 and 2.2 chan-
nels were not present, suggesting that TROX-1 eﬃcacy is
derived primarily by block of Cav2.2 channels (Abbadie
et al., 2010). Importantly, it appears to have an improved
therapeutic window compared to ziconitide (Swensen
et al., 2012). Notably, TROX-1 signiﬁcantly reversed
mechanical allodynia and hind-limb weight-bearing asym-
metry in a rat model of knee OA (Abbadie et al., 2010),
suggesting that Cav2.2 channel activity also has an impor-
tant role in mediating OA pain. Therefore, the aim of this
study was to compare the eﬀects of TROX-1 on spinal
electrophysiological measures of nociception in a rat
model of MIA-induced OA pain. In vivo electrophysiology
allows for spinal nociceptive processing and central sen-
sitisation to be studied experimentally and provides infor-
mation on eﬃcacy against suprathreshold responses,
which are likely to equate to high levels of pain transmis-
sion as reported by patients, therefore adding to behav-
ioral data where the analgesic eﬀect of drugs on
threshold responses are generally measured.EXPERIMENTAL PROCEDURES
A total of 23 Sprague–Dawley rats (Central Biological
Services, University College London, UK) were
employed for this study. All experimental procedures
were licensed by local laws (UK Animals (Scientiﬁc
Procedures) Act 1986 and the European Communities
Council Directive of 24 November 1986 (86/609/EEC))
and followed the guidelines under the International
Association for the Study of Pain (Zimmermann, 1983).
Induction of OA
OA was induced as previously described (Rahman and
Dickenson, 2015). Brieﬂy, isoﬂuorane (2% v/v delivered
in a 3:2 ratio of nitrous oxide and oxygen) anesthetized
male Sprague–Dawley rats (130–150 g) received an
intra-articular injection of 2 mg monosodium iodoacetate
in 25 ll of 0.9% saline through the infrapatellar ligament
of the knee. Sham animals were injected with sterile
0.9% saline only. Following injection animals were
allowed to recover and then re-housed in cages under a
12-h alternating light/dark cycle with ad libitum access to
food and water.
Behavioral assessment of OA pain
Animals were habituated to the test environment for at
least 30 minutes prior to model induction and behavioral
testing (carried out on day 7 and day 14 post model
induction).
Behavioral assessment of OA pain was carried out as
previously described (Rahman and Dickenson, 2015).
Brieﬂy, hind limb weight bearing was measured using an
incapacitance tester (Linton Instruments, Norfolk, UK)
and the weight bearing on the ipsilateral hind limb to knee
injection is presented as a percentage of the total weight
borne on both hind limbs. Tactile hypersensitivity of the
ipsi and contralateral hind paw was tested with von Frey
ﬁlaments (vFs) (Touch-test TM, North Coast Medical
Inc., San Jose, CA, USA) using the ‘‘up-down method’’
(Chaplan et al., 1994), starting with 2.0 g then ranging
from 0.4 g to 15 g. Data are presented as mean 50%
paw withdrawal threshold (PWT) for each
group ± S.E.M. (standard error of the mean).
In vivo electrophysiology
Two weeks after MIA or sham injection in vivo
electrophysiological studies were performed as
previously described (Rahman and Dickenson, 2014).
Brieﬂy, animals were initially anesthetized with isoﬂur-
oane (4% v/v) delivered in a 3:2 ratio of nitrous oxide
and oxygen. A laminectomy, under isoﬂuroane anesthe-
sia of 2–3% was then performed to expose the L4–5 seg-
ments of the spinal cord. Anesthetic levels of 1.5–1.7%
were maintained for the duration of the experiment.
Extracellular recordings of the evoked activity of lamina
V–VI dorsal horn neurons to electrical and natural
mechanical and thermal stimulation of the ipsilateral hind
paw were made using parylene-coated tungsten elec-
trodes (A-M Systems, Sequim, WA, USA). All the neu-
rones recorded in this study were of wide dynamic
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and noxious inputs (pinch and noxious heat); further all
neurones responded to natural stimuli in a graded manner
with coding of increasing intensity.
The evoked response to a train of 16 transcutaneous
electrical stimuli (2-ms wide pulses, 0.5 Hz, applied at
three times the threshold current for C-ﬁber activation of
the dorsal horn cell) was delivered via stimulating
needles inserted into the peripheral receptive ﬁled. The
neuronal responses evoked by Ab- (0–20 ms), Ad- (20–
90 ms) and C-ﬁbers (90–350 ms) were separated and
quantiﬁed on the basis of latency. Responses occurring
after the C-ﬁber latency band were taken to be the post-
discharge of the cell (350–800 ms). The center of the
peripheral receptive ﬁeld was then stimulated using
mechanical punctate and thermal stimuli (vFs, 2, 8, 26
and 60 g and heat, applied with a constant water jet, 40,
45 and 48 C). All natural stimuli were applied for a
period of 10-s per stimulus. Data were captured and
analyzed by a CED 1401 interface coupled to a Pentium
computer with Spike 2 software (Cambridge Electronic
Design; PSTH and rate functions). The data for the von
Frey forces are expressed on a linear scale since the
aim was to investigate drug eﬀects on diﬀerent
intensities of stimuli.
Pharmacological assessment was carried out on one
neuron only per animal. The testing procedure was
carried out every twenty minutes and consisted of a
train of electrical stimuli followed by natural stimuli as
described above. Following three consecutive stable
control trials (<10% variation for the C-ﬁber-evoked
response, and <20% variation for all other parameters)
neuronal responses were averaged to give the pre-drug
control values. TROX-1 ((3R)-5-(3-chloro-4-ﬂuorophe
nyl)-3-methyl-3-(pyrimidin-5-ylmethyl)-1-(1H-1,2,4-triazol-
3-yl)-1,3-dihydro-2H-indol-2-one)(Synthesized in house;
Gru¨nenthal GmbH, Germany), diluted in 0.9% saline
solution containing in 5% DMSO (dimethylsulfoxide) and
10% cremophor, was then administered systemically via
subcutaneous injection (20 mg/kg) or via topical spinal
application (0.1 and 1 lg/50 ll), the vehicle for spinally
applied drug was diluted to <1% cremophor and <1%
DMSO. The eﬀect of each dose was followed for an
hour, with tests carried out at 10, 30 and 50 min before
the next dose (spinal administration only) was applied
cumulatively. A trend for the greatest eﬀect was seen at
either the 10- or 30-min time point (for both routes).
Using this protocol the evoked responses are stable for
many hours, the lack of drug eﬀect in the sham group
evidences this stability.
The vehicle was used for spinal and systemic dosing
of TROX-1. Any eﬀect of the vehicle on the observed
neuronal eﬀects can be excluded since the drug had no
eﬀect in sham animals on any measure by either route.
In the MIA animals where the drug was eﬀective, the
eﬀects seen were modality selective. Further, a previous
study by our group, albeit in a rat model of spinal nerve-
induced hypersensitivity, found no eﬀect of the vehicle
on behavioral measures of pain after systemic or spinal
routes of administration in SNL rats (Patel et al., 2015)
nor on electrophysiological recordings of evoked neuronalactivity in naı¨ve rats after systemic dosing with the vehicle
(unpublished data). Additionally, others have shown that
10% (Menendez et al., 1999) and 50% DMSO (Peng
et al., 1997) did not change spinal neuronal activity, and
even greater concentrations of intrathecal DMSO did not
aﬀect the behavioral response to formalin injection
(Lozano-Cuenca et al., 2005). Taken together, we con-
cluded that the vehicle alone was highly unlikely to have
had an eﬀect alone, and was not the cause of the inhibi-
tory eﬀects of TROX-1 seen in the present paper. For
these reasons vehicle experiments were not undertaken.
Statistical analysis
All statistical tests were performed on raw data using
GraphPad Prism 5 (GraphPad software, USA).
Behavioral data were analyzed using the Mann–Whitney
test. For in vivo electrophysiology measures, statistical
signiﬁcance was tested using either a paired or unpaired
Student’s t-test to compare two groups of data and a
one-way or two-way repeated-measures (RM) analysis
of variance (ANOVA), followed by Bonferroni-corrected
paired t-tests when simultaneously comparing more
than two groups of data. For the in vivo pharmacological
studies the maximal eﬀect, compared with pre-drug
baseline control, for each drug dose was selected; this
varied and was seen at all the time points tested i.e. 10,
30 and 50 min post drug administration. However, in
most cases the maximal change in response was
observed at 10 or 30 min post drug application. Drug
eﬀects were then expressed as the mean maximal
eﬀect of the pre-drug control for each dose. A two-way
ANOVA with repeated measures (RM ANOVA) followed
by a Bonferroni test for multiple comparisons was used
to analyze drug eﬀect on the mechanical- and thermal-
evoked neuronal responses. Drug eﬀect on the
electrical-evoked responses was assessed using a one-
way RM ANOVA followed by Bonferroni test for multiple
comparisons after spinal TROX-1 or a paired Student’s
t-test after systemic TROX-1 administration. Values of
p< 0.05 were considered signiﬁcant.
RESULTS
MIA-induced pain behavior
Intra-articular injection of MIA produced a signiﬁcant
decrease in hind PWT to mechanical stimulation
compared with the contralateral hind paw in MIA rats
and sham control (Fig. 1a). The behavioral
hypersensitive response to mechanical stimulation of
the hind paw ipsilateral to MIA injection is indicative of
secondary allodynia and central sensitization. A
signiﬁcant reduction in weight bearing of the ipsilateral
hind limb in MIA-injected rats was seen compared with
the sham control group (Fig. 1b) indicative of enhanced
discomfort evoked by weight on the limb in the MIA group.
In vivo electrophysiology – evoked responses of dorsal
horn neurones. The eﬀect of TROX-1, delivered via
spinal or systemic route, was assessed upon the
evoked responses of deep dorsal horn neurones to
Fig. 1. Behavioral assessment at day 14 after MIA (n= 12) or saline
injection (n= 11). Intra-articular injection of MIA injection produced a
signiﬁcant reduction in the paw withdrawal threshold to mechanical
punctate stimulation (a) and a decrease in the amount of weight
borne on the hind limb ipsilateral to injection (b) compared with the
saline-injected sham controls. ⁄p< 0.05 compared with shams,
Mann–Whitney test. Values are mean ± SEM.
Table 1. A comparison of the baseline electrophysiological responses
of deep dorsal horn WDR neurons in sham and MIA rats. A signiﬁcantly
greater response was observed for some neuronal measures after MIA
injection. The electrical-evoked responses are expressed as the mean
number of action potentials (APs) ± S.E.M. evoked by a train of 16
electrical stimuli given at three times the threshold for C-ﬁber-evoked
neuronal response. The natural evoked responses are expressed as
the mean number of AP ± S.E.M. evoked during the 10-s period the
stimulus was applied to the peripheral receptive ﬁeld. Asterisk (⁄)
denotes signiﬁcance compared with sham control data, ⁄P< 0.05,
⁄⁄P< 0.01, ⁄⁄⁄P< 0.001 (unpaired Student’s t-test for electrical and
brush-evoked responses, two-way ANOVA with Bonferroni post test for
the natural mechanical and thermal-evoked neuronal responses)
Sham
(n= 12)
MIA (n= 12)
Electrical-
evoked
responses
Depth (lm) 804 ± 36 797 ± 41
C-ﬁber
threshold
(mA)
1.1 ± 0.1 1.3 ± 0.2
Ab-ﬁber-
evoked
response
(AP)
164 ± 10 178 ± 15
Ad-ﬁber-
evoked
response
(AP)
146 ± 67 214 ± 20
C-ﬁber-
evoked
response
(AP)
523 ± 49 732 ± 62⁄
Post
discharge
(AP)
336 ± 33 456 ± 72⁄
Input (AP) 360 ± 45 606 ± 47⁄⁄
Wind-up
(AP)
515 ± 60 578 ± 82
Evoked
responses to
mechanical
stimuli
Dynamic
brush
142 ± 25 212 ± 40
vF 2 g (AP) 26 ± 7 29 ± 6
vF 8 g (AP) 187 ± 39 437 ± 59⁄
vF 26 g (AP) 641 ± 84 1077 ± 104⁄⁄⁄
vF 60 g (AP) 1041 ± 107 1310 ± 95⁄
Evoked
responses to
thermal
stimuli
40 C (AP) 211 ± 67 253 ± 48
45 C (AP) 456 ± 69 559 ± 65
48 C (AP) 1019 ± 94 1083 ± 130
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of their peripheral receptive ﬁeld. A total of 23 WDR
neurones were recorded. The mean threshold for C-
ﬁber activation was similar between groups as was the
mean depth of the neurones, which corresponded with
lamina V–VI of the dorsal horn (Table 1). Comparison of
the average baseline pre-drug responses for MIA and
shams revealed a signiﬁcantly greater Ad- and C-ﬁber-
evoked response, and an enhanced Input measure of
neuronal excitability in the MIA group. A signiﬁcantly
greater response evoked by mechanical punctate
stimulation was seen in the MIA group (F1,3 = 21.13
P< 0.0001) (Table 1), but all other baseline neuronal
responses were not signiﬁcantly diﬀerent between
groups. However, it should be noted that this study was
not powered to compare baseline neuronal responses
between MIA and sham groups, for this reason any
diﬀerences in the average baseline neuronal responses
were not further analyzed or emphasized. Although
spontaneous and enhanced evoked activity of joint
nociceptors and dorsal horn neurones has been
previously reported (Schuelert and McDougall, 2006,
2008; McDougall et al., 2009; Rahman et al., 2009;
Schuelert and McDougall, 2009; Sagar et al., 2010;
Kelly et al., 2012; Bullock et al., 2014), as hassensitisation of spinal nociceptive withdrawal reﬂexes
(Kelly et al., 2013) indicating that the MIA model is asso-
ciated with peripheral and central hyperexcitability.Spinal administration of TROX-1 signiﬁcantly inhibits
the mechanical and thermal-evoked responses of dorsal
horn neurones in the MIA group only. Following the
characterization of single WDR neurons, the cumulative
eﬀects of 0.1 lg and 1 lg TROX-1 applied directly onto
to the spinal cord were examined. Spinal TROX-1 did
not have any signiﬁcant eﬀect on any of the electrical-
evoked neuronal responses in either the sham or MIA
groups. In contrast, the neuronal responses evoked by
natural stimulation of the peripheral receptive ﬁeld in the
MIA group were sensitive to the inhibitory eﬀect of
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TROX-1 inhibited neuronal responses evoked by
dynamic brush stimulation of the peripheral receptive
ﬁeld (F2,5 = 4.237 P= 0.046; Fig. 2d) and mechanical
punctate stimuli, (F2,3 = 30.5 P< 0.0001; Fig. 2f) seen
as signiﬁcant decreases in evoked response to
stimulation vF 8, 26 and 60 g. A signiﬁcant inhibition of
the evoked neuronal response to noxious heat
stimulation after spinal TROX-1 application was also
only observed in the MIA group (F2,2 = 12.84
P< 0.0001; Fig. 2h) seen as signiﬁcant decreases in
evoked response to stimulation at 45 C and 48 C,
whereas the response evoked by innocuous heat
stimulation (40 C) of the hind paw was unaﬀected by
the drug (Fig. 2h). In comparison, TROX-1 had no
signiﬁcant eﬀect on any of the evoked neuronal
responses in the sham control group. (Fig. 2d, e, g).
Systemic administration of TROX-1 signiﬁcantly inhi-
bits the mechanical evoked responses of dorsal horn
neurones in the MIA group only. Systemic administration
of TROX-1 (20 mg/kg) mirrored some of the eﬀects seen
with spinal administration of the drug. The evoked
neuronal response to mechanical punctate stimulation
was signiﬁcantly reduced in the MIA group (F1,3 = 128
P 6 0.0001; Fig. 3f) seen as signiﬁcant decreases in
evoked response to stimulation with vF 8, 26 and 60 g.
Although a reduction in the evoked neuronal response
to brush stimulation was seen in the MIA group with
systemic TROX-1, overall this did not reach signiﬁcance
(Fig. 3d). No signiﬁcant eﬀect was seen with the drug
on any of the electrical or thermal-evoked neuronal
response in the MIA group (Fig. 3b, h) or on any
neuronal measure in the sham group (Fig. 3a, c, e, f).
DISCUSSION
OA is a progressive and degenerative disease of the
whole joint. It is characterized by destruction and
degradation of the articular cartilage, synovial lining,
connective tissues and subchondral bone remodeling
(Vincent and Watt, 2014). In this study we injected the gly-
colysis inhibitor, MIA (2 mg), into the knee joint, which
causes chondrocyte death (Grossin et al., 2004) through
an imbalance of anabolic and catabolic pathways, a phe-
nomenon thought to represent a causative factor of OA
(Guingamp et al., 1997; Goldring, 2000). Further, the
rapid and progressive death of chondrocytes produces
cartilage degeneration and perturbations of the subchon-
dral bone, consistent with the clinical histopathology of
OA and associated pain (Guingamp et al., 1997; Janusz
et al., 2001; Kobayashi et al., 2003). Thus the MIA model
has, so far, proved useful for the understanding of
osteoarthritic pain mechanisms (Zhang et al., 2013). In
the present study joint pathology was not assessed, how-
ever, MIA injection produced hypersensitivity to mechan-
ical stimulation of the ipsilateral hind paw and a decrease
in hind limb weight bearing of the injected side, conﬁrming
pain development and in addition, we have previously
observed loss of articular cartilage using this dose of
MIA in rats at day 14 post injection (Thakur et al., 2012)
as have others (Fernihough et al., 2004; Pomonis et al.,2005; Im et al., 2010), therefore it is highly likely that the
animals used in the present study developed OA of the
knee and supports the relevance of this model of MIA-
induced arthritis for studying OA pain mechanisms
(Vincent et al., 2012; Malfait et al., 2013).
Pain symptoms in knee OA patients are largely
located within the area surrounding the aﬀected joint,
however many OA patients also exhibit areas of
referred pain and tenderness, which correlates with the
hypersensitivity of the ipsilateral hind paw in MIA rats,
and implicates mechanisms of central sensitisation
contributing to the pain experience (Farrell et al., 2000;
Bajaj et al., 2001; Gwilym et al., 2009; Graven-Nielsen
and Arendt-Nielsen, 2010; Aranda-Villalobos et al.,
2013) Indeed, experimental human studies in OA patients
suggest that central sensitization is an important contrib-
utor to their pain and a direct link between sensitization
levels in referred areas and clinical pain intensity experi-
enced by OA patients was shown (Arendt-Nielsen et al.,
2010). We have recorded the electrophysiological activity
of deep dorsal horn WDR neurones, which has been
shown to correlate with the intensity and temporal aspects
of pain in animals and human subjects (Coghill et al.,
1993a,b; Sikandar et al., 2013), therefore the data pre-
sented here provide for an electrophysiological correlate
for the spread of sensitisation seen in OA patients and
allow for spinal nociceptive mechanisms to be studied
experimentally.
Spinal and systemic administration of TROX-1
reduced the evoked response to innocuous mechanical
stimulation with dynamic brush and vF 8 g in the MIA
group, although the eﬀect on brush-evoked responses
did not quite reach signiﬁcance after systemic
administration. Nonetheless, these electrophysiological
data suggest that TROX-1 would attenuate nociceptive
behaviors evoked by low-threshold mechano-stimulation
of the hind paw, and correlates with the reversal of
tactile allodynia previously reported in a rat model of OA
(Abbadie et al., 2010). Suprathreshold mechanical-(vF
26 and 60 g) evoked neuronal responses in the MIA group
were also sensitive to the inhibitory eﬀects of spinal and
systemic TROX-1 suggesting that the drug would also
attenuate mechanical hyperalgesia and therefore may
have analgesic eﬃcacy against the more severe pains
experienced by some patients.
Spinal administration of TROX-1 attenuated a range
of mechanical and thermal-evoked responses in the MIA
group indicating that a key site of action of the drug is
on VGCCs located on central terminals of primary
aﬀerents and/or second-order neuronal networks and
possibly DRG. In comparison, systemic administration of
the drug was only eﬀective at inhibiting mechanical
punctate-evoked neuronal responses, suggesting that
mechano-evoked neuronal responses are more
sensitive to the inhibitory actions of TROX-1, which may
include antagonism of Cav2.2 channels located on
peripheral terminals of joint aﬀerents (Just and
Heppelmann, 2003) as well as those on central terminals
by the systemic route. The inhibition of both thermal and
mechanical responses only by spinal application may indi-
cate high local concentrations are able to attenuate both
Fig. 2. TROX-1 signiﬁcantly reduced the dynamic brush, mechanical punctate and thermal-evoked neuronal responses in the MIA group. Following
stable baseline recordings, OA or sham rats were dosed spinally with 0.1 lg, and 1 lg TROX-1 in a volume of 50 ll. The evoked neuronal response
to electrical (a, b), dynamic brush (c, d), mechanical punctate (e, f) and thermal stimulation (g, h) of the peripheral receptive ﬁeld in sham (n= 6, left
panel) and MIA (n= 6, right panel) rats were recorded. Asterisks and bars denote statistically signiﬁcant main eﬀect (one-way RM ANOVA). (+)
denotes signiﬁcant diﬀerence between baseline and 0.1 lg:+P< 0.05, ++P< 0.01. (⁄) denotes signiﬁcant diﬀerence between baseline and 1 lg
TROX-1: ⁄P< 0.05, ⁄⁄P< 0.01, ⁄⁄⁄P< 0.001 (two-way RM ANOVA with Bonferroni post-hoc test). All data are presented as mean ± SEM.
PD= post-discharge, I = Input and W= wind up.
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doses. What is clear is that regardless of the route of
administration, TROX-1 was only eﬀective in the arthritic
condition. This ‘‘functional selectivity’’ may be due to its
state (biased toward open/inactivated channelconformation) and use-dependent activity (Abbadie
et al., 2010; Patel et al., 2015), conditions which are more
likely in the arthritic state, compared with the sham group,
as an increased incidence of spontaneous activity and
enhanced responsiveness of joint nociceptors and dorsal
Fig. 3. TROX-1 signiﬁcantly reduced the dynamic brush and mechanical punctate-evoked neuronal responses in the MIA group. Following stable
baseline recordings, OA or sham rats were administered a single does of 20 mg/kg TROX-1. The evoked neuronal response to electrical (a, b),
dynamic brush (c, d), mechanical punctate (e, f) and thermal stimulation (g, h) of the peripheral receptive ﬁeld in sham (n= 6, left panel) and MIA
(n= 5, right panel) rats. Asterisk (⁄) denotes signiﬁcant diﬀerence between baseline and 20 mg/kg TROX-1: ⁄⁄P< 0.01, ⁄⁄⁄P< 0.001 (two-way RM
ANOVA with Bonferroni post-hoc test). All data are presented as mean ± SEM. PD = post-discharge, I = Input and W= wind up.
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(Schuelert and McDougall, 2006, 2008; McDougall
et al., 2009; Rahman et al., 2009; Schuelert and
McDougall, 2009; Sagar et al., 2010; Kelly et al., 2012;
Bullock et al., 2014), and we have observed compara-
tively greater responses of some neuronal measures in
the MIA group in the present study (Table 1), whichmay, in part, underlie the pathophysiological selectivity
of TROX-1. Importantly this suggests that, if used in
patients, TROX-1 would attenuate abnormal pathophysio-
logical transmission but not normal physiological trans-
mission i.e. acute pain. In line with this hypothesis
evidence from studies using Cav2.2 (/) mice and
x-conotoxins also suggest that blocking Cav2.2 activity
W. Rahman et al. / Neuroscience 305 (2015) 76–85 83would be more eﬀective against pathological pain com-
pared with acute pain (Sluka, 1997, 1998; Hatakeyama
et al., 2001; Kim et al., 2001; Saegusa et al., 2001;
Scott et al., 2002).
The MIA-dependent antinociceptive eﬀect of TROX-1
could also reﬂect an increased expression of Cav2.2
channels within the spinal cord. An increase in Cav2.2
density and a greater functional role within the dorsal
horn, ipsilateral to injury, has been demonstrated in
models of chronic inﬂammation and nerve injury
(Matthews and Dickenson, 2001; Abbadie et al., 2010;
Lu et al., 2010). It is not known if a similar increase in
Cav2.2 channels occurs in the MIA model of OA speciﬁ-
cally. However, we have previously seen a signiﬁcant
increase in expression levels of the alpha-2delta auxillary
subunit of VGCCs within the dorsal horn of MIA rats
(Rahman et al., 2009) which may, at least in part, underlie
the MIA-selective antinociceptive eﬀect of TROX-1.
Interestingly, a recent study demonstrated a link between
spinal N-type channel activity, behavioral hypersensitivity
and overexpression of VGCC- alpha-2delta overexpres-
sion (Chang et al., 2015).
Noxious thermal-evoked neuronal responses in the
MIA group were sensitive to the inhibitory eﬀect of
TROX-1 after spinal administration but not systemic
administration, suggesting that central spinal Cav2.2
channels play an important role in heat hyperalgesia,
consistent with the observed anti-nociceptive eﬀects of
TROX-1 in inﬂammation-induced heat hyperalgesia in
mice (Abbadie et al., 2010). Surprisingly, we did not
observe a similar inhibitory eﬀect on neuronal responses
after systemic TROX-1; this may be due to the lower
dose, (20 mg/kg), used in our study.
The electrical-evoked neuronal responses were
resistant to the inhibitory eﬀect of spinal or systemic
administration of TROX-1 this is in marked contrast to
its inhibitory eﬀects on the natural-evoked neuronal
responses in the MIA group. This could be because the
barrage of activity induced by the train of 16 electrical
stimuli is maybe too great for the drug at the doses
given to elicit any signiﬁcant eﬀect. Alternatively the two
forms of evoked activity may result in a comparatively
diﬀerent proportion of channels entering the open/
inactivated conformational state. We have previously
observed enhanced neuronal after discharge (prolonged
depolarisations after removal of the stimulus) in MIA
rats following mechanical and thermal stimuli applied for
10 s (Rahman et al., 2009). The proportion of channels
entering an inactivated state increases with prolonged
stimulus (Freeze et al., 2006) therefore this mechanism
may enable the state-dependent inhibitor TROX-1 to
exert its eﬀect on natural stimuli but not rapid electrical
stimulus in vivo.
There is mounting evidence for a sub-group of OA
patients, refractory to traditional analgesics such as
NSAIDs and opioids, who exhibit neuropathic signs and
symptoms (Hochman et al., 2011; Ohtori et al., 2012;
Roubille et al., 2014). The dose of MIA used here
(2 mg) produces OA associated with markers of neuropa-
thy (Ivanavicius et al., 2007; Im et al., 2010; Thakur et al.,
2012, 2014), therefore the ﬁndings from the present studycould translate better to OA patients with a neuropathic
component underlying their pain. Interestingly, a recent
electrophysiological study by our group using TROX-1 in
a rat spinal nerve ligation model of neuropathic pain
(Patel et al., 2015) mirrored many of the eﬀects of the
dug reported here, suggesting that these chronic pain
states share certain common pathological mechanisms,
likely to be central rather than peripheral.
CONCLUSION
TROX-1 given via spinal and systemic routes of
administration signiﬁcantly reduced neuronal measures
of nociception in the MIA group only, suggesting
plasticity in Cav2 (likely Cav2.2) channels in the arthritic
condition. Further, the ﬁndings from the present study
support the hypothesis that Cav2.2 blockers would be
useful for the treatment of OA pain.
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